Daptomycin Population Pharmacokinetics in Patients Affected by Severe Gram-Positive Infections: An Update
Authors:
Open Access
- 7 July 2022
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 11 (7) , 914
Abstract
Daptomycin pharmacokinetics may not depend on renal function only and it significantly differs between healthy volunteers and severely ill patients. Herein, we propose a population pharmacokinetics model based on 424 plasma daptomycin concentrations collected from 156 patients affected by severe Gram-positive infections during a routine therapeutic drug monitoring protocol. Model building and validation were performed using NONMEM 7.2 (ICON plc), Xpose4 and Perl-speaks-to-NONMEM. The final pop-PK model was a one-compartment first-order elimination model, with a 2.7% IIV for drug clearance (Cl), influence of creatinine clearance on drug clearance and of sex on distribution volume. After model validation, we simulated 10,000 patients with the Monte-Carlo method to predict the efficacy and tolerability of different daptomycin daily dosages. For the most common 6 mg/kg daily dose, the simulated probability of overcoming the toxic minimum concentration (24.3 mg/L) was 14.8% and the efficacy (expressed as a cumulative fraction of response) against methicillin-resistant S. aureus, S. pneumoniae and E. faecium was 95.77%, 99.99% and 68%, respectively. According to the model-informed precision dosing paradigm, pharmacokinetic models such as ours could help clinicians to perform patient-tailored antimicrobial dosing and maximize the odds of therapy success without neglecting toxicity risks.Keywords
This publication has 26 references indexed in Scilit:
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and EndocarditisClinical Infectious Diseases, 2010
- Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic FeverAntimicrobial Agents and Chemotherapy, 2009
- The lasso—a novel method for predictive covariate model building in nonlinear mixed effects modelsJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Mutant Selection Window Hypothesis UpdatedClinical Infectious Diseases, 2007
- Eucast Technical Note on daptomycinClinical Microbiology and Infection, 2006
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an updateJournal of Antimicrobial Chemotherapy, 2005
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004
- Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2003
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998